Front Oncol: Stereotactic radiotherapy (SBRT) combined with immunotherapy (SBRT-IO) compared with TACE in the treatment of patients with locally advanced hepatocellular carcinoma

Advanced hepatocellular carcinoma (HCC) has entered the age of immunotherapy

The study included patients with locally advanced HCC who were inoperable, refractory, or who refused surgical treatment

The study included 226 patients, 210 were initially treated with TACE, and 16 were treated with SBRT-IO

Among the 64 patients matched by PSM, the median tumor diameter was 10 cm (range: 3.

Multivariate analysis found that SBRT-IO was a good independent predictor of OS (HR = 0.

The ORR of the SBRT-IO group was significantly higher than that of the TACE group (87.

Among patients receiving TACE, the risk of TRAE ≥3 and treatment interruption due to toxicity was more common (60.

In summary, studies have shown that stereotactic radiotherapy (SBRT) combined with immunotherapy (SBRT-IO) in the treatment of patients with locally advanced hepatocellular carcinoma has a certain clinical effect, and its safety is controllable and tolerable, and it is worthy of further exploration

Original source:

Chiang CL, Chiu KW-H, Lee FA-S, Kong F-MS and Chan AC-Y (2021) Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.